Group 1 - On August 26, 2025, the top three companies by trading volume in the Southbound Stock Connect were Yingfu Fund (02800) with a trading volume of 5.01 billion, SMIC (00981) with 3.86 billion, and Alibaba-W (09988) with 3.29 billion [1] - In the Southbound Stock Connect for Shenzhen-Hong Kong, the top three companies were Alibaba-W (09988) with a trading volume of 2.19 billion, SMIC (00981) with 1.95 billion, and Tencent Holdings (00700) with 1.81 billion [1] Group 2 - The top active companies in the Southbound Stock Connect (Hong Kong) included Yingfu Fund (02800) with a net buy of 4.997 billion, Alibaba-W (09988) with a net buy of 448 million, and Tencent Holdings (00700) with a net buy of 911 million [2] - In the Southbound Stock Connect (Shenzhen), Alibaba-W (09988) had a net buy of 897 million, while SMIC (00981) and Tencent Holdings (00700) had net sells of 275 million and 240 million respectively [2]

Core Insights - The Hong Kong stock market saw significant net inflows from northbound capital, totaling HKD 165.73 billion on August 26, with the Shanghai-Hong Kong Stock Connect contributing HKD 96.05 billion and the Shenzhen-Hong Kong Stock Connect contributing HKD 69.67 billion [1] Group 1: Stock Performance - The most net bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Alibaba-W (09988) [1][5] - The most net sold stocks were SMIC (00981), Oriental Selection (01797), and Xiaomi Group-W (01810) [1][5] - The Tracker Fund of Hong Kong received a net inflow of HKD 50.04 billion, while SMIC experienced a net outflow of HKD 15.76 billion [2][3] Group 2: Sector Trends - Technology stocks, particularly Alibaba-W, Tencent (00700), and Meituan-W (03690), saw substantial net purchases of HKD 13.45 billion, HKD 6.7 billion, and HKD 4.09 billion respectively [5] - The approval of new regulations for internet platform pricing is expected to lead to more standardized pricing practices among e-commerce platforms, which may help maintain market shares [5] - The biotechnology sector is highlighted by the net purchase of HKD 1.25 billion in Innovent Biologics (01801), following the FDA's approval of a new drug trial [6] Group 3: Company-Specific Developments - Meituan (01357) was included in the MSCI China Index, which is expected to enhance its market visibility and investment appeal [5] - Xiaomi Group-W reported a 40% year-on-year increase in automotive revenue, although its smartphone business faced challenges with declining margins [7] - Oriental Selection's performance was mixed, with a 55% year-on-year drop in GMV, leading to a downgrade in its target price by Goldman Sachs [7]

Market Overview - The Hong Kong stock market failed to maintain its strong performance from the previous day, with all three major indices experiencing a collective adjustment. The Hang Seng Index fell by 1.18% or 304.99 points, closing at 25,524.92 points, with a total trading volume of HKD 31.78 billion. The Hang Seng China Enterprises Index decreased by 1.07% to 9,148.66 points, while the Hang Seng Tech Index dropped by 0.74% to 5,782.24 points [1] Blue-Chip Stocks Performance - CSPC Pharmaceutical Group (01093) led the decline among blue-chip stocks, falling by 4.33% to HKD 10.38, with a trading volume of HKD 1.797 billion, contributing a loss of 6.04 points to the Hang Seng Index. Bank of America Securities reported a 14.3% year-on-year decline in total revenue for CSPC in Q2, with attributable net profit down 24% to RMB 1.1 billion. The firm revised its revenue forecasts for 2025 to 2027 down by 25%, 2%, and 11% respectively [2] Sector Highlights - Large technology stocks mostly declined, with Alibaba down 2.57% and Tencent down 0.81%. Gold stocks surged, with China Gold International rising over 10%. Apple is expected to initiate a three-year innovation cycle, boosting related stocks like Lens Technology, which rose over 5%. Gaming stocks and some new consumption concepts performed well, with Melco International Development up over 9% [3][5] Federal Reserve Insights - Federal Reserve Chairman Jerome Powell indicated rising downside risks in the U.S. labor market, suggesting a potential policy adjustment could be appropriate. This statement is seen as a strong signal for a possible interest rate cut as early as September. The market reacted positively, particularly for precious metals, with expectations for further increases in gold prices [4] Gaming Sector Performance - The gaming sector continued its upward trend, with Melco International Development rising 9.27% to HKD 5.54. According to JPMorgan, Macau's gaming revenue for the first 24 days of August reached MOP 17.65 billion, with a daily average of MOP 735 million, reflecting a 9% increase from the previous week [6] Pharmaceutical Sector Challenges - The pharmaceutical sector faced pressure, with several stocks declining. Notably, CStone Pharmaceuticals (09966) fell 6.74% to HKD 10.24. U.S. President Trump's announcement to drastically reduce drug prices could create significant challenges for the global pharmaceutical industry, presenting both opportunities and risks for Chinese biotech stocks [6] Notable Stock Movements - Double Ended Co. (06960) debuted with a 31.29% increase, closing at HKD 19.05. The company focuses on energy storage solutions in the data and communication sectors, with a projected market share of 11.1% by 2024 [7] - Kingsoft Holdings (03918) reached a new high, rising 17.94% to HKD 5.72, reporting a 16.76% year-on-year revenue increase to USD 342 million [8] - Angelalign Technology (06699) saw a 10.28% increase to HKD 75.1, with a 33.1% year-on-year revenue growth reported [9] - Meitu Inc. (01357) rose 7.9% to HKD 11.47 after being included in the MSCI China Index, with Morgan Stanley expressing confidence in its long-term growth potential [10] - Xintai Medical (02291) experienced a significant drop of 12.75% to HKD 23.96 following a major shareholder's sale of shares [11]

中信里昂：维持泡泡玛特跑赢大市评级 升目标价至368港元 智通财经8月26日讯(编辑 童古 汤赞淇)以下为各家机构对港股的最新评级和目标价： 高盛：维持东方甄选沽售评级 升目标价至9港元 高盛就东方甄选(01797.HK)发布研报称，下调公司2026至2027财年GMV预测1%至3%，受益于自营品牌 产品GMV贡献提升，将收入预测上调最多10%，2026至2027财年经调整净利润率预测上调0.2%和1%， 目标价上调至9港元。因基本面持续疲软，加上估值较贵，该行维持沽售评级。 中金公司就布鲁可(00325.HK)发布研报称，公司2025年上半年收入同比增长27.9%至13.4亿元，经调整 净利润同比增长10%。尽管利润率因低毛利产品占比提升及费用投入加大而承压，但海外业务收入同比 大增899%，产品结构持续优化，IP商业化进程稳步推进。中金公司看好其全人群、全价位、全球化战 略带来的长期成长潜力，维持"跑赢行业"评级，目标价135港元。 海通国际：维持金斯瑞生物科技优于大市评级 海通国际就金斯瑞生物科技(01548.HK)发布研报称，公司2025年上半年收入同比增长81.9%至5.19亿美 元，持续经营业务经 ...

美图公司(01357)早盘涨超7%，截至发稿，涨6.59%，报11.33港元，成交额10亿港元。 消息面上，全球知名指数公司MSCI此前宣布2025年8月份的指数审议结果。其中，美图公司获纳入 MSCI中国指数，将于今日(26日)收市后正式生效。此外，美图公司上半年收入18.21亿元人民币，同比 增加12.34%；股东应占溢利3.97亿元，同比增加30.84%。收入增幅主要来自以订阅为主的影像与设计产 品业务实现快速收入增长， 摩根士丹利发布研报称，美图公司目标2025至2028年将总付费比率提升至8至10%，意味著订阅收入有 望较2024年的4.7%翻倍增长。公司同时正重建海外的生活场景产品线，以针对美国及欧盟市场；现有 生活场景产品在美国市场的付费比率约达50%。该行看好美图公司的长期增长潜力，基于管理层清晰的 发展路径、专注的战略定位、运用生成式AI的能力以及审慎的业务范围，重申"增持"评级，将目标价由 14.4港元升至15.7港元，相当于预测明年动态市盈率1.6倍，以反映管理层将2025年净利润指引上调约 11%。 ...

Group 1: Market Overview - The Hang Seng Index fell by 0.22%, down 56 points, closing at 25,773 points, while the Hang Seng Tech Index rose by 0.27% [1] - The early trading volume in the Hong Kong stock market reached 133.9 billion HKD [1] Group 2: Company Performances - Pop Mart (09992) surged by 2.88%, with new products selling out instantly and continued high growth in H1 performance [1] - China Duty Free Group (01880) soared over 5% following the opening of its first city duty-free store in Guangzhou, with multiple city stores entering the cultivation phase [1] - Genscript Biotech (01672) increased by 4.7%, as the company raised funds to enhance its weight loss drug development, with Citigroup suggesting attention on the upcoming ASC30 Phase II data [1] - China Gold International (02099) rose by 6.8%, reaching a new high, with core product output exceeding half of the annual guidance and significant expansion potential at the Jiamar mine [1] - Meitu (01357) saw an early gain of over 7%, officially entering the MSCI China Index, with Morgan Stanley optimistic about the company's long-term growth potential [1] - Innovent Biologics (02696) increased by 5.68% post-earnings, with ongoing internationalization strategy and overseas product profits more than doubling in H1 [1] - Angelalign Technology (06699) rose over 7%, with H1 net profit increasing by over 360%, and declared a special interim dividend of 0.46 HKD [1] - Oriental Selection (01797) fell over 7%, with annual net profit declining by 99.67%, while Goldman Sachs maintained a "sell" rating [1][2] Group 3: Financial Results - Kintor Pharmaceutical (01951) dropped by 5.97% post-earnings, reporting a loss of 1.04 billion CNY in H1, compared to a profit in the same period last year [2]

Group 1: Hong Kong Stocks - China Gold International (02099) rose nearly 7%, reaching a new high as core product output exceeded half of the annual guidance, with significant expansion potential at the Jiama mine [1] - Pop Mart (09992) increased by nearly 2%, with new products selling out instantly and continued high growth in H1 performance [1] - Meitu (01357) surged over 7% after officially entering the MSCI China Index, with Morgan Stanley optimistic about the company's long-term growth potential [1] - China Tobacco Hong Kong (06055) climbed nearly 6.5%, setting a new high since its listing, with stable growth in H1 performance and promising expansion opportunities as an overseas platform for China Tobacco International [1] - China National Chemical Corporation (03983) fell over 1% as mid-term shareholder profit decreased by 6.74% year-on-year, with a significant drop in urea sales prices [1] - China Intelligent Transportation (01900) surged over 42% after a profit warning, expecting mid-term shareholder profit of approximately 361 million yuan [1] - Keep (03650) dropped nearly 5% post-earnings despite successfully turning a profit in H1, focusing its strategy on AI [1] - Western Cement (02233) rose nearly 6.5% post-earnings, with mid-term shareholder profit increasing by 93.4% due to high growth in overseas sales [1] - ChinaSoft International (00354) increased over 4% post-earnings, with H1 net profit rising over 10% and HarmonyOS 5 terminal devices exceeding 12 million units [1] Group 2: US Stocks - NIO (NIO.US) fell 3.94% after Citigroup set a target price of $8.1, listing five reasons to buy [3] - Shanghai's optimization of real estate policies led to significant gains for housing service platforms, with Fangduo (DUO.US) rising 28.28% and Beike (BEKE) up 1.57% [3] - Hesai (HSAI.US) rose 0.52%, with expectations of 300,000 to 400,000 units shipped in the entire robot lidar market this year, and over 200,000 units for the robot market [3] - Pinduoduo (PDD.US) increased by 0.87% ahead of its earnings report, with optimistic market expectations reflected in declining Put/Call ratios [3] - Intel (INTC.US) fell 1.01% as the federal government acquired a 10% stake in the struggling chip giant, becoming its largest shareholder [4] - American Airlines (AAL.US) dropped 4.06% after an emergency landing due to a passenger's electronic device catching fire [4] - Netflix (NFLX.US) rose 1.11%, achieving its first box office champion in North America [4] - Spirit Airlines (FLYY.US) plummeted 14.02% as financial restructuring failed to lead to sustainable development [4] - Keurig Dr Pepper (KDP.US) fell 11.48% after announcing a €15.7 billion (approximately $18.4 billion) cash acquisition of Dutch coffee giant JDE Peet's NV [4] - Roblox (RBLX.US) increased by 6.02%, with Wedbush maintaining an "outperform" rating and a target price of $165, citing strong user ecosystem and business model growth potential [4] - Opendoor (OPEN.US) dropped 9.38% despite a significant prior increase, with July existing home sales rising 2% month-on-month to an annualized 4.01 million units [5]

大摩称，美图一方面利用AI技术深化产品功能以提高国内用户付费意愿，设定未来三年内总付费率翻倍至8-10%的目标；另一方面 调整海外策略，从单纯追求付费用户转向并重月活跃用户增长，意图打开欧美等市场的新增长空间。而AI工具RoboNeo被视为提 升个性化推荐和加速付费率增长的关键，计划9月开始商业化。 投资者正密切关注即将到来的2025年9月，届时美图计划启动其AI工具RoboNeo的商业化，并开始将其整合入其他应用，同时与 阿里巴巴的合作也将有实质性进展，这些举措被视为检验其新战略成效的关键节点。 核心目标：三年内付费率翻倍 据摩根士丹利报告，美图管理层给出了明确的财务指引，其增长战略的核心是提升用户的付费意愿。 公司设定的首个里程碑是，在三年内（2025-2028年）将整体付费率提升至8-10%。报告指出，这是在2024年4.7%基础上的巨大 飞跃。长期来看，美图的目标更为远大：休闲类产品付费率达到10%以上，生产力工具付费率达到20%以上。 在生成式AI浪潮和全球化布局的交汇点上，美图公司正向市场描绘一幅清晰的增长蓝图。 摩根士丹利8月25日发布的研报，美图管理层提出了一个关键目标：在未来三年内，将公司产 ...

智通财经APP获悉，摩根士丹利发布研报称，看好美图公司(01357)的长期增长潜力，基于管理层清晰的 发展路径、专注的战略定位、运用生成式AI的能力以及审慎的业务范围，重申"增持"评级，将目标价由 14.4港元升至15.7港元，相当于预测明年动态市盈率1.6倍，以反映管理层将2025年净利润指引上调约 11%。 该行指，美图公司目标2025至2028年将总付费比率提升至8至10%，意味着订阅收入有望较2024年的 4.7%翻倍增长。公司同时正重建海外的生活场景产品线，以针对美国及欧盟市场; 现有生活场景产品在 美国市场的付费比率约达50%。 ...

Group 1 - Meitu Company (01357) saw a morning surge of over 7%, currently trading at 11.33 HKD with a transaction volume of 1 billion HKD [1] - MSCI announced that Meitu will be included in the MSCI China Index, effective after market close today [1] - For the first half of the year, Meitu reported revenue of 1.821 billion RMB, a year-on-year increase of 12.34%, and a net profit attributable to shareholders of 397 million RMB, up 30.84% year-on-year [1] Group 2 - Morgan Stanley's report indicates that Meitu aims to increase its total paid user ratio to 8-10% by 2025-2028, suggesting a potential doubling of subscription revenue compared to 4.7% in 2024 [1] - The company is also rebuilding its overseas lifestyle product line to target the US and EU markets, with a current paid user ratio of about 50% in the US market [1] - Morgan Stanley maintains a positive outlook on Meitu's long-term growth potential, citing a clear development path, focused strategic positioning, and the use of generative AI, raising the target price from 14.4 HKD to 15.7 HKD, reflecting an 11% upward adjustment in the 2025 net profit guidance [1]